78 related articles for article (PubMed ID: 24317328)
1. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Pichler M; Winter E; Stotz M; Eberhard K; Samonigg H; Lax S; Hoefler G
Br J Cancer; 2012 May; 106(11):1826-32. PubMed ID: 22549179
[TBL] [Abstract][Full Text] [Related]
2. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
Taniguchi H; Yamazaki K; Yoshino T; Muro K; Yatabe Y; Watanabe T; Ebi H; Ochiai A; Baba E; Tsuchihara K;
Cancer Sci; 2015 Mar; 106(3):324-7. PubMed ID: 25800101
[TBL] [Abstract][Full Text] [Related]
3. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.
Blanke CD; Goldberg RM; Grothey A; Mooney M; Roach N; Saltz LB; Welch JJ; Wood WA; Meropol NJ;
Oncologist; 2011; 16(8):1061-8. PubMed ID: 21737577
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and biomarkers in colorectal cancer.
Grady WM; Pritchard CC
Toxicol Pathol; 2014 Jan; 42(1):124-39. PubMed ID: 24178577
[TBL] [Abstract][Full Text] [Related]
5. Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Wheeler DL; Dunn EF; Harari PM
Nat Rev Clin Oncol; 2010 Sep; 7(9):493-507. PubMed ID: 20551942
[TBL] [Abstract][Full Text] [Related]
6. Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.
Kasi PM; Afable MG; Herting C; Lukanowski M; Jin Z
Oncologist; 2023 Dec; 28(12):1034-1048. PubMed ID: 37774394
[TBL] [Abstract][Full Text] [Related]
7. Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations.
Carpanese D; Rossi V; Di Paolo V; Quintieri L; Penna A; Zuccolotto G; Sebellin J; Saran C; Pipitone F; Miolo G; De Diana E; Realdon N; Rigamonti N; Di Sarra F; Coppola M; Rosato A
Int J Pharm; 2024 Jan; 649():123643. PubMed ID: 38040395
[TBL] [Abstract][Full Text] [Related]
8. CD19 occupancy may drive CARs further.
Hirayama AV; Bleakley M
Blood; 2024 Jan; 143(3):190-192. PubMed ID: 38236611
[No Abstract] [Full Text] [Related]
9. Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.
Peeters M; Karthaus M; Rivera F; Terwey JH; Douillard JY
Drugs; 2015 May; 75(7):731-48. PubMed ID: 25895463
[TBL] [Abstract][Full Text] [Related]
10. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
11. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.
Esposito C; Rachiglio AM; La Porta ML; Sacco A; Roma C; Iannaccone A; Tatangelo F; Forgione L; Pasquale R; Barbaro A; Botti G; Ciardiello F; Normanno N
Cancer Biol Ther; 2013 Dec; 14(12):1143-6. PubMed ID: 24025416
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
13. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
14. Not all antibodies are equal.
Booth L
Cancer Biol Ther; 2013 Dec; 14(12):1075-6. PubMed ID: 24317328
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
Oncologist; 2012; 17(1):14. PubMed ID: 22210091
[TBL] [Abstract][Full Text] [Related]
16. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
